CIC:	Hospital UPN:	Patient UIC	HSCT Date: yyyy - mm - dd
	HSCT - Min	imum Essential REGISTRATION - DAY 0	
		Centre Identification	
	Unit:	-	
		Patient Data	
No Yes:  Hospital Unique Pati Compulsory, registratic All transplants perform the patient and not to		ut this item. e registered with the same patient identific	Jnknown
Date of birth:	yyyy - mm - dd	Sex: Male	Female
	Prir	mary Disease Diagnosis	
PRIMARY DISEASE DI  Acute Leukaem Acute Myelo related Prece Precursor Ly Therapy related Secondary Acute Chronic Leukae Chronic Lym Chronic Lym Lymphoma Non Hodgkin	nia ogenous Leukaemia (AML) ursor Neoplasms mphoid Neoplasms (old ALL) d myeloid neoplasms (old te Leukaemia) emia eloid Leukaemia (CML) phocytic Leukaemia (CLL)	☐ Myeloma/Plasma cell disorder ☐ Solid Tumour ☐ Myelodysplastic syndromes /	Histiocytic disorders  Autoimmune disease  Juvenile Idiopathic Arthritis  Multiple Sclerosis  Systemic Lupus  Systemic Sclerosis  Haemoglobinopathy
Other diagnosis	, specify:		

CIC:	Hospital UPN:	Pa	tient UIC		HSCT Date:	vvvv - mm - dd
	PLASMA CELL DISOR		.UDING N	<b>JULTIPLE</b>		
		Dis	sease	<u>,                                      </u>		
Date of Initia	ıl Diagnosis: yyyy - mm - dd					
Classifica  Multiple  MM  MM  MM  Plasma  Solitary  Primary  POEMS  Monoclo	myeloma (MM) - heavy chain and light chain - light chain - non-secretory cell leukaemia plasmacytoma of bone amyloidosis	Check light and Check light char disease (LCDD/I	in type only →		IgG	HT CHAIN TYPE Kappa Lambda strom)
	ging for Multiple myeloma only SALMON & DURIE STAGE			ISS	STAGE	
	(optional)				nlob mg/L)	Albumin (g/L)
	Stage Symptoms  I A  III B			< 3. < 3. 3.5 - < > 5.	5 OR 5.5	>35 < 35 any
	Chromosome Analy	sis at Diagn	nosis (not	for Primary	v amvloidosis	,
Chromosome Analysis at Diagnosis (not for Primary amyloidosis)  Chromosome analysis at diagnosis (All methods including FISH)  Normal Abnormal Not done or failed Unknown  If abnormal:  Complex kariotype: No Yes Unknown  (3 or more abnormalities)  You can transcribe the complete karyotype:				,		
Indicate be	OR low those abnormalities that have b	een <b>evaluated</b> a	nd whether ti	hev were <b>Abser</b>	nt or <b>Present</b>	
	Del 13q14  t(11;14)  abn 17q  del 17p  t(4:14)  t(14:16)  1q amplification  myc rearrangement  Other, specify		Absent	Present	Not evaluat	ed ed ed ed ed ed ed ed ed
NA	Molecular Marker	s at Diagnos	sis (not to	r Primary a	amyloidosis)	
Marker ana	lysis at diagnosis  t Present	Not Evaluated	d [	Unknown		
		Page	2 P	CD_Day 0 Allo M	ED-A Form	

CIC:	Hospital UPN:	Patient UIC	HSCT Date: yyyy - mm - dd	-
PLASI		ICLUDING MULTIPLE M'disease code 4)		
	Sta	tus At HSCT		
Date of this HSCT:	yyyy - mm - dd			
STATUS		NUMBER		
Never treated				
Stringent complete rer	nission (sCR)	1st		
<ul><li>Complete remission (C</li><li>Very good partial remi</li></ul>	•	☐ 2nd		
Partial remission (PR) Relapse from CR (untre	eated)	3rd or higher		
Progression No change / stable disc	ease			

CIC: Hosp	ital UPN: Pat	ent UIC	HSCT Date:	уууу -	mm - d	d
	HS	SCT				
Performance score  Score			80 🗆 90 🗀	<b>100</b>	1	
Weight (Ng).	ricigii (ciii).					
	Comorbi	dity Index				
forror et al., Blood, 2005 Oct 15;	106(8): 2912-2919: http://www.	ncbi.nlm.nih.gov/pmc/article	es/PMC1895304/			
Vas there any <i>clinically significan</i> preparative regimen?  No Yes	$m{t}$ co-existing disease or organ imp	airment at time of patient a	ssessment just prior	to the		
Comorbidity	Defi	nitions		No	Yes	N/E
Solid tumour, previously present	Treated at any time point in the melanoma skin cancer		ling non-			
	Indicate type					
nfammatory bowel disease	Crohn's disease or ulcerative col	itis				
Rheumatologic	SLE, RA, polymyositis, mixed CTI	D, or polymyalgia rheumatica	3			
nfection	Requiring continuation of antim	icrobial treatment after day	0			
Diabetes	Requiring treatment with insulir diet alone	or oral hypoglycaemics but	not			
Renal: moderate/severe	Serum creatinine > 2 mg/dL or > transplantation	177 μmol/L, on dialysis, or p	rior renal			
Hepatic: mild	Chronic hepatitis, bilirubin betw ULN, or AST/ALT between ULN a	ind 2.5 × ULN				
moderate/ severe	Liver cirrhosis, bilirubin greater × ULN	tnan 1.5 × ULN, or ASI/ALI §	greater than 2.5			
Arrhythmia	Atrial fibrillation or flutter, sick sarrhythmias	inus syndrome, or ventricul	ar			
Cardiac	Coronary artery disease, conges 50%, or shortening fraction in cl		l infarction, EF ≤			
Cerebrovascular disease	Transient ischemic attack or cer	ebrovascular accident				
Heart valve disease	Except mitral valve prolapse					
Pulmonary: moderate	DLco and/or FEV1 66-80% or dy	spnoea on slight activity				
severe	DLco and/or FEV1 ≤ 65% or dysp	noea at rest or requiring ox	ygen			
Dbesity	Patients with a body mass index	> 35 kg/m2				
Peptic ulcer	Requiring treatment					
Psychiatric disturbance	Depression or anxiety requiring	psychiatric consultation or t	reatment			

Were there any other major clinical abnormalities prior to the preparative regimen? Specify.....

CIC:	Hospital UPN:	Patient UIC	HSCT	
				yyyy - mm - dd
	Type	of HSCT (Alloge	eneic)	
☐ Allogeneic				
Patient CMV status	☐ Negative	Positive Not eva	luated Unknow	n
Multiple donors (including multiple CB	units) No [	Yes: Number of donors		
		Donor 1		
HLA MATCH TYPE (DONOR  HLA - Identical sibling ( Syngeneic (monozygoti HLA - Matched other re HLA - Mismatched rela	(may include non-monozygo ic twin) elative	of mismatch 1 HLA locu	us mismatch oci mismatch	
Donor ID given by th	he centre			
<b>HLA</b> MISMATCHES BET (Mismatched relatives only)	WEEN DONOR AND PATIEN	Г		
Complete number	of mismatches inside each l	оох		
A B	C DRB1 DQB1 I	OPB1		
0=match; 1=one mismatch; .	2=2 mismatches; N/E=not evalu	Antigenic  Allelic		
Unrelated donor				
ION code of the Donor Regist	•			
BMDW code of the Donor Re Name of Donor Registry/ CB		N code is unknown) (up to 4 ch	•	
Donor centre na	,,,,			
	(1) applicable) option	<i>aı)</i> y or the CB Bank listed above		
		try or the CB Bank listed above		
		LTS WITH HLA TYPING into the		
Donor information				
Date of birth		OR Age at time of donation	(if date of birth not pr	•
Donor Sex	(at birth) Male	Female		i.i.(3)
Donor CMV sta	itus Negative	e Dositive	□ Not evaluated	Unknown
Did this donor provide more th	an one stem cell product		_	-
☐ No - <i>(pleas</i>	se fill "Donor 1 – Product of different stem cell produ	• =	AND 2" on next nage)	

CIC:	Hospital UPN:	Patient UIC	HSCT Date:	yyyy - mm - dd
	Dor	or 1 - Product Number	r 1	
If more than o	one stem cell product, this is the FIRST			
	em Cells for <b>this product</b> , select only <b>c</b>			
l _		ripheral blood		
☐ Cord	blood Other:			
	oulation ex-vivo of this product including for RBC removal or volume reduction	ʒ T-cell depletion		
☐ Yes	Negative: No	Yes:		
		T-cell (CD3+) depletion (do no	t use for "Campath in bag")	
		<ul><li>T-cell receptor αβ depletion</li><li>B-cell depletion (CD19+) by M</li></ul>	10 A B	
		B-ceil depletion (CD15+) by W	IOAB	
		NK cell depletion by MoAB Other		
	Positive: No Ye	s CD34+ enrichment		
	Genetic manipulation	☐ No ☐ Yes		
	Doo	nor 1 - Product Numbe	ur O	
If more than	one stem cell product, this is the SECOI		81 Z	
	em Cells for <b>this product</b> , select only <b>c</b>	<u> </u>		
	•	ripheral blood		
☐ Cord	blood Other:			
other than f	oulation ex-vivo of this product including			
☐ Yes	Negative: No	Yes:  T-cell (CD3+) depletion (do no	ot use for "Campath in haa")	
		T-cell receptor αβ depletion	case for campain in say ,	
		B-cell depletion (CD19+) by M	1oAB	
		NK cell depletion by MoAB Other		
	Positive: No Ye	s CD34+ enrichment		
		0_0.000		
	Genetic manipulation	☐ No ☐ Yes		

Please enter the LABORATORY RESULTS WITH HLA TYPING into the database

CIC:	Hospital UPN:		Patient UIC	HSCT Date: yyyy - mm - dd
			Donor 2	
HLA MATCH TYPE (DONOR REL	ATION WITH PATIE	NT)		
<ul><li>☐ HLA - Identical sibli</li><li>☐ Syngeneic (mc</li><li>☐ HLA - Matched oth</li><li>☐ HLA - Mismatched</li></ul>	onozygotic twin) er relative	de non-monozy <u>e</u> ee of mismatch	gotic twin)  1 HLA locus mismat  >=2 HLA loci misma	
HLA MISMATCHES BETWEE (Mismatched relatives only)	N DONOR AND PAT	TENT		
Complete number of m	ismatches inside ea	ach box		
А В (	DRB1 DQB	1 DPB1		
		Ar	ntigenic	
	$\overline{1}\overline{\Box}\overline{\Box}$		lelic	
0=match; 1=one mismatch; 2=2 n	nismatches; N/E=not e	-	iche.	
Unrelated donor				
ION code of the Donor Regis	stry or CB Bank			
BMDW code of the Donor R		-		cters)
Name of Donor Registry/ CB  Donor centre na		tne above code. le, optional)	s is unknown)	
	() :		Listed above	
_	y the Donor Registr by the Donor Regis			
Please	ntor the LABORATO	NDV DECLIITS W	ITH HLA TYPING into the data	phasa
r	inter the LABORATO	ORT RESOLIS W	THE HEATTFING IIIO CITE GAL	avase
Donor information				
Date of birth	y - mm - dd	<u>OR</u>		(if date of birth not provided) (s)month(s)
Donor Sex (at birth)	☐ Male	Female	,	
Donor CMV status	Negative	Positive	☐ Not evaluated	Unknown
Did this donor provide more that	an one stem cell pro	oduct		
	fill "Donor 1 – Pro		· -	
	of different stem cel ducts e.g. BM PB, pl		ed from this donor 1 – Product Number 1 AND 2	 " on next page)

If more than one stem cell product, this is the FIRST product Infused from this donor	CIC:	Hospital UPN:	Patient UIC	HSCT Date:	уууу - mm - dd
If more than one stem cell product, this is the FIRST product infused from this donor    Source of Stem Cells for this product, select only one   Bone marrow   Peripheral blood   Cord blood   Other source   Graft manipulation ex-vivo including T-Cell depletion other thon for RBC removal or volume reduction   No   Yes   Negative:   No   Yes   CD34+ enrichment   Reduction   B. cell depletion (CD39+) by MoAB   No. cell depletion (CD39+) depletion (CD39+) depletion (CD39+) depletion (CD39+) by MoAB   No. cell depletion (CD39+)		Donor	2 - Product Numb	ar 1	
Source of Stem Cells for this product, select only one   Bone marrow				OI I	
Bone marrow   Peripheral blood   Cord blood   Other source			uct infused from this donor		
Cord blood   Other source   Graft manipulation ex-vivo including T-Cell depletion other than for RBC removal or volume reduction   No   Yes   T-cell (CD3+) depletion (do not use for "Compathbag")   T-cell receptor αβ depletion   No   Yes   Positive:   No   Yes   CD34+ enrichment   Positive:   No   Yes   T-cell receptor αβ depletion   No   Yes   Positive:   No   Yes   CD34+ enrichment   T-cell receptor αβ depletion   No   Yes   T-cell receptor αβ depletion   No   No   No   No   No   No   No	Source o	of Stem Cells for this product, select only one			
Graft manipulation ex-vivo including T-Cell depletion  other than for RBC removal or volume reduction  No					
other than far RBC removal or volume reduction   No		_			
No   Yes   Negative:   No   Yes:   T-cell (CD3+) depletion (do not use for "Campathbag")   T-cell receptor αβ depletion   Secul depletion (D13+) by MoAB   Not cell depletion by MoAB   Other					
Yes	I				
T-cell receptor aß depletion   B-cell depletion (CD19+) by MoAB   Not cell depletion (CD19+) by MoAB   Not cell depletion by MoAB   Other   Positive:   No   Yes   CD34+ enrichment   Genetic manipulation   No   Yes   Please enter the LABORATORY RESULTS WITH HLA TYPING into the database   Donor 2 - Product Number 2					
B-cell depletion (CD19+) by MoAB   NX cell depletion by MoAB   NX cell depletion by MoAB   Other   NX cell depletion   NX cell depletion by MoAB   Other   NX cell depletion   NX cell depletion by MoAB   Other   NX cell depletion   NX cell depletion by MoAB   Other   NX cell depletion   NX cell depletion by MoAB   Other   NX cell depletion   NX cell deple					
Other   Positive:   No   Yes   CD34+ enrichment   Genetic manipulation   No   Yes			_		
Positive:   No   Yes   CD34+ enrichment   Genetic manipulation   No   Yes					
CD34+ enrichment			Utner		
Please enter the LABORATORY RESULTS WITH HLA TYPING into the database    Donor 2 - Product Number 2		Positive: No Yes	CD241 oprichment		
Please enter the LABORATORY RESULTS WITH HLA TYPING into the database    Donor 2 - Product Number 2					
Donor 2 - Product Number 2  If more than one stem cell product, this is the SECOND product infused from this donor    Source of Stem Cells for this product, select only one   Bone marrow   Peripheral blood   Cord blood   Other source   Cord blood   Other source   Peripheral blood   Cord blood   Other source   Cord blood   Other source   Cord blood   Other source   Cord blood   Cord b		Genetic manipulation No	☐ Yes		
If more than one stem cell product, this is the SECOND product infused from this donor    Source of Stem Cells for this product, select only one		Donor	2 - Product Numb	er 2	
Source of Stem Cells for this product, select only one  Bone marrow Peripheral blood Cord blood Other source  Graft manipulation ex-vivo including T-Cell depletion other than for RBC removal or volume reduction No Yes Negative: No Yes:  T-cell (CD3+) depletion (do not use for "Campathbag") T-cell receptor αβ depletion B-cell depletion (CD19+) by MoAB NK cell depletion by MoAB Other  Positive: No Yes  CD34+ enrichment	If more th				
Graft manipulation ex-vivo including T-Cell depletion  other than for RBC removal or volume reduction  No Yes Negative: No Yes:  T-cell (CD3+) depletion (do not use for "Campathbag")  T-cell receptor αβ depletion B-cell depletion (CD19+) by MoAB  NK cell depletion by MoAB  Other  Positive: No Yes  CD34+ enrichment	□ Во	one marrow Peripheral blood			
other than for RBC removal or volume reduction  No Yes Negative: No Yes:  T-cell (CD3+) depletion (do not use for "Campathbag")  T-cell receptor αβ depletion B-cell depletion (CD19+) by MoAB NK cell depletion by MoAB Other  Positive: No Yes  CD34+ enrichment	Graft ma	enipulation ex-vivo including T-Cell depletion			
CD34+ enrichment	other the	an for RBC removal or volume reduction	T-cell (CD3+) depletion (do  T-cell receptor αβ depletio  B-cell depletion (CD19+) by  NK cell depletion by MoAB	n / MoAB	
		Positive: No Yes			
Genetic manipulation No Yes			CD34+ enrichment		
		Genetic manipulation No	Yes		

Please enter the LABORATORY RESULTS WITH HLA TYPING into the database

CIC: Hospital UPN:	Patient UIC	HSCT Date:
HS	SCT (Continued)	
Chronological number of HSCT for this patient?	P No Yes: CIC if	No
If >1, please submit an Annual follow up form be subsequent transplant as the date of last conta (This is so we can capture relapse data and other HSCT part of a planned multiple (sequential) graft protein	act er events between transplants).	f the
□ No □ Yes	ocoi (program):	
Prep	parative Regimen	
Preparative (conditioning) regimen given?  No (Usually Paed Inherited Disorders only) Go to G	GvHD Prophylaxis	
Was this intended to be myeloablative? (allo only)  Yes  No: Reason	Age of recipient Comorbid conditions Prior HSCT Protocol driven Other, specify	
<b>Drugs</b> ☐ No ☐ Yes ☐ (include any active agent be it chemo, monoclonal antibody, po	Unknown  olyclonal antibody, serotherapy, etc.)	

CIC:	Hospital UPN:	Patient UIC	HSCT Date:	
				yyyy - mm - dd

## Specification and dose of the preparative regimen

TOTAL PRESCRIBED CUMULATIVE DOSE* as per protocol:				
DRUG (given before day 0)	DOSE		UNIT	S
Ara-C (cytarabine)	2002	mg/m2	mg/kg	
ALG, ATG (ALS/ ATS)		mg/m2	mg/kg	
Animal origin: Horse				
Rabbit				
Other, specify				
Bleomycin		mg/m2	☐ mg/kg	
Busulfan		mg/m2	☐ mg/kg	mg x hr/L
Oral IV Both				micromol x min/L mg x min/mL
BCNU		mg/m2	mg/kg	
Bexxar (radio labelled MoAB)		☐ mCi	☐ MBq	
CCNU		mg/m2	mg/kg	
Campath (AntiCD 52)		mg/m2	mg/kg	
☐ Carboplatin		mg/m2	☐ mg/kg	mg x hr/L micromol x min/L mg x min/mL
☐ Cisplatin		mg/m2	☐ mg/kg	
☐ Clofarabine		mg/m2	mg/kg	
Corticosteroids		mg/m2	mg/kg	
☐ Cyclophosphamide		mg/m2	mg/kg	
☐ Daunorubicin		mg/m2	mg/kg	
Doxorubicin (adriamycine)		mg/m2	☐ mg/kg	
Epirubicin		mg/m2	mg/kg	
Etoposide (VP16)		mg/m2	mg/kg	
☐ Fludarabine		mg/m2	mg/kg	
Gemtuzumab		mg/m2	mg/kg	
☐ Idarubicin		mg/m2	mg/kg	
☐ Ifosfamide		mg/m2	☐ mg/kg	
☐ Imatinib mesylate		mg/m2	mg/kg	
☐ Melphalan		mg/m2	mg/kg	
Mitoxantrone		mg/m2	mg/kg	
☐ Paclitaxel		mg/m2	☐ mg/kg	
Rituximab (mabthera, antiCD20)		mg/m2	mg/kg	
☐ Teniposide		☐ mg/m2	☐ mg/kg	
☐ Thiotepa		mg/m2	mg/kg	
☐ Treosulphan		mg/m2	☐ mg/kg	
Zevalin (radiolabelled MoAB)		☐ mCi	MBq	
Other radiolabelled MoAB		☐ mCi	☐ MBq	
Specify				
Other MoAB, specify		mg/m2	mg/kg	
Other, specify		mg/m2	mg/kg	

<sup>\*</sup>Report the total prescribed cumulative dose as per protocol. Multiply daily dose in mg/kg or mg/m² by the number of days; e.g. for Busulfan given 4mg/kg daily for 4days, total dose to report is 16mg/kg

<sup>\*\*</sup>AUC = Area under the curve

CIC:	Hospital UPN:	Patient UIC	HSCT Date:
Total Body Irradiation (TBI)	N.	□ Vee . Tatal grandled . P. C.	
Total Body IITadiation (TBI)	☐ No	Yes : Total prescribed radiation dose as	
		Number of fractions	over radiation days
TLI, TNI, TAI	☐ No	Yes: Total prescribed radiation dose a	as per protocolGy
(lymphoid, nodal, abdominal)			
GvHD prophylaxis or pre	ventive treatn	ent (Allografts only)	
□ No □ Yes	ventive treati	che (mografic om))	
If Yes: Drugs (Immun	osuppressive che	no)	
ALG, ALS Anti CD2 Campati Systemic Cyclospo Cycloph Etanero FK 506 Inflixima Methoto Mycoph Sirolimu Other no	S, ATG, ATS: (giv 25(MoAB in vivo) h (MoAB in vivo; c corticosteroids orine osphamide (give ept (MoAB in vivo; (Tacrolimus, Prog ab (MoAB in vivo; rexate enolate (MMF) s nonoclonal antibo gent (in vivo), spe I photopheresis (	en after day 0) Animal origin: Horse  an be "in the bag")  n after day 0)  raf)  dy (in vivo), specify	Rabbit Other, specify
Other, specify			
		Survival Status	
Survival Status on date o	•	Sulvival Status	
Patient died between  Main Cause of Dea  Relapse or Progr HSCT Related Ca Unknown Other	th (check on ession/Persistent use		
GVHD	ry cause or bea	check as many as appropriate).	
Pulmona Infection bac vira fur pan Un Rejection History Haemor Cardiac Central	cterial al agal rasitic known n/Poor graft func of severe Veno oc rhage toxicity nervous system (0 atestinal (GI) toxic icity	clusive disorder (VOD) NS) toxicity	